# Safety and Immunogenicity of CJ-40010 in Healthy Subjects

> **NCT04182932** · PHASE1 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Hand, Foot and Mouth Disease

## Interventions

- **BIOLOGICAL:** CJ-40010 EV71 vaccine A dose
- **BIOLOGICAL:** CJ-40010 EV71 vaccine B dose
- **BIOLOGICAL:** CJ-40010 CVA16 vaccine C dose
- **BIOLOGICAL:** CJ-40010 CVA16 vaccine D dose
- **BIOLOGICAL:** CJ-40010 Bivalent vaccine E dose
- **BIOLOGICAL:** CJ-40010 Bivalent vaccine high dose
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04182932
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-02
- **Primary completion:** 2021-11
- **Final completion:** 2021-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182932, "Safety and Immunogenicity of CJ-40010 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04182932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*